Iconovo AB (publ)

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.